Fenbendazole (Pancur) and mebendazole are drugs used to treat parasites and worms in humans. Scientists have discovered that fenbendazole may also be effective in treating certain types of cancer, including pancreatic cancer. It is the primary ingredient of the Joe Tippens Cancer Protocol, and is sometimes referred to as “the Genome Guardian”.
The third most lethal cancer, pancreatic cancer kills almost 90 percent of patients within five years of diagnosis. It resists most treatments, including chemotherapy and newer immunotherapy approaches. Researchers are studying the molecular basis of this resistance, with the help of NCI-funded grants such as the Pancreatic Specialized Programs of Research Excellence (SPORE) and others.
A new study suggests that blocking a major pathway in pancreatic cancer could make tumors more sensitive to chemotherapy and other treatments. The results are based on studies in human pancreatic cancer cells and in genetically engineered mice.
Scientists found that a drug known as fenbendazole, an antiparasitic medicine, prevents the onset and spread of pancreatic cancer in mice. The study also showed that the drug could be used in combination with other agents to treat pancreatic cancer.
The results are published in the journal Cancer Discovery. The scientists identified multiple mechanisms by which fenbendazole disrupted microtubules and inhibited cell growth, including by stabilizing p53, inhibiting epithelial-mesenchymal transition, and interfering with glucose metabolism. The data suggest that fenbendazole is a candidate for clinical trials in pancreatic cancer and other tumors. fenbendazole for pancreatic cancer